Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir + Sofosbuvir +/- Ribavirin in IFN-intolerant/ineligible HCV
NCT02214420Phase 4Completed
- Sponsor
- SC Liver Research Consortium
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of simeprevir in hepatitis C (HCV) (2 arms), sponsored by SC Liver Research Consortium. Primary endpoint: Sustained Viral Response. Started Oct 2014; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02214420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214420.